Research has indicated that malignant pleural effusion is a predictive factor for reduced PFS in NSCLC patients receiving first-line pembrolizumab or second-line nivolumab treatment30,31, which may be related to the relatively higher levels of VEGF in the blood plasma of patients with malignant pleural effusion. Here, VEGFA is linked to non-small cell lung carcinoma.